BioSpace News Archive

The global tyrosine kinase inhibitors market was valued at US$ 18.3 Bn in 2017.

Significant players operating in the global T-cell acute lymphoblastic leukemia market incorporate Novartis AG, Pfizer, Inc., F. Hoffmann-La Roche Ltd., Erytech Pharma, Inc., Sanofi, and Celgene Corporation.

The demand within the global market for scleroderma diagnostics and therapeutics has been rising on account of advancements in the field of rheumatoid treatments, finds Transparency Market Research.

As per the latest research study by TMR, the membrane microfiltration market is anticipated to witness an impressive growth at a CAGR of over 7.5% through 2028.

Transparency Market Research has published a new report titled, “Post-operative Nausea and Vomiting Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”, in June 2018.

FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (“ FSD Pharma ” or the “ Company ”) today announced that it has entered into an Equity Distribution Agreement dated July 10, 2020 (the “ Sales Agreement ”) with A.G.P./Alliance Global Partners (the “ Sales Agent ”). Under the Sales Agreement the Company may, at its discretion and from time-to-time during the term of the Sales Agreement, sell, through the Sales Agent, Class B Subo

Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization, announces the promotion of Dr. John Mott to Vice President of Development.

Equillium, Inc., a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced that as reported by its partner, Biocon Limited, a clinical trial conducted in India by Biocon demonstrated that itolizumab significantly reduced mortality in patients hospitalized with COVID-19.

Vela Diagnostics announced that an automated version of its COVID-19 detection test, the ViroKey™ SARS-CoV-2 RT-PCR Test v2.0, has received the CE mark for in vitro diagnostic use as well as Provisional Authorisation from the Health Sciences Authority in Singapore.

Pfizer Inc. and BioNTech SE announced that two of the companies’ four investigational vaccine candidates from their BNT162 mRNA-based vaccine program being developed to help protect against SARS-CoV-2, received Fast Track designation from the U.S. Food and Drug Administration.